|
1
|
Lippman ME: Efforts to combine endocrine
and chemotherapy in the management of breast cancer: Do two and two
equals three? Breast Cancer Res Treat. 3:117–127. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Johnston SR and Dowsett M: Aromatase
inhibitors for breast cancer: Lessons from the laboratory. Nat Rev
Cancer. 3:821–831. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rock E and De Michelle A: Nutritional
approaches to late toxicities of adjuvant chemotherapy in breast
cancer survivors. J Nutr. 133(Suppl 1): S3785–S3793. 2003.
|
|
5
|
Heyler LK, Chin S, Chu BK, Fitzgerald B,
Verma S, Rakovitch E, Dranitsaris G and Clemons M: The use of
complementary and alternative medicine among patients with locally
advanced breast cancer: A descriptive study. BMC Cancer. 6:392006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oudin C, Bonnetain F, Boidot R, Vegran F,
Soubeyrand MS, Arnould L, Riedinger JM and Lizard-Nacol S: Patterns
of loss of heterozygosity in breast carcinoma during neoadjuvant
chemotherapy. Int J Oncol. 30:1145–1151. 2007.PubMed/NCBI
|
|
7
|
Mathews AK, Sellergren SA, Huo D, List M
and Fleming G: Complementary and alternative medicine use among
breast cancer survivors. J Alt Comp Med. 13:555–562. 2007.
View Article : Google Scholar
|
|
8
|
Lippman ME, Osborne CK, Knazek R and Young
N: In vitro model systems for the study of hormone-dependent breast
cancer. N Engl J Med. 296:154–159. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suto A, Bradlow HL, Kubota T, Kitajima H,
Wong GY, Osborne MP and Telang NT: Alteration in proliferative and
endocrine responsiveness of human mammary carcinoma cells by
prototype tumor suppressing agents. Steroids. 58:215–219. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li G, Sepkovic DW, Bradlow HL, Telang NT
and Wong GYC: Lycium barbarum inhibits growth of estrogen receptor
positive human breast cancer cells by favorably altering estradiol
metabolism. Nutr Cancer. 61:408–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mukherjee B, Telang N and Wong GY: Growth
inhibition of estrogen receptor positive human breast cancer cells
by Taheebo from the inner bark of Tebebuia avellandae tree. Int J
Mol Med. 24:253–260. 2009.PubMed/NCBI
|
|
12
|
Telang NT, Li G, Sepkovic DW, Bradlow HL
and Wong GY: Anti-proliferative effects of Chinese herb Cornus
officinalis in a cell culture model for estrogen receptor positive
clinical breast cancer. Mol Med Rep. 5:22–28. 2012.PubMed/NCBI
|
|
13
|
Telang N, Li G, Sepkovic D, Bradlow HL and
Wong GY: Comparative efficacy of extracts from Lycium barbarum bark
and fruit on estrogen receptor positive human mammary carcinoma
MCF-7 cells. Nutr Cancer. 66:278–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Katdare M, Osborne M and Telang NT: Soy
isoflavone genestein modulates cell cycle progression and induces
apoptosis in HER-2/neu oncogene expressing human breast epithelial
cells. Int J Oncol. 21:809–815. 2002.PubMed/NCBI
|
|
15
|
Sorlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical interpretations. Proc
Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Neve RM, Chin K, Fridyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Subik K, Lee JF, Baxter L, Strzepak T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and
Tang P: The expression patterns of ER, PR, HER-2, CK5/6, EGFR, Ki
67 and AR by immunohistochemical analysis in breast cancer cell
lines. Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
|
|
18
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schneider J, Kinne D, Frachia A, Pierce V,
Anderson KE, Bradlow HL and Fishman J: Abnormal oxidative
metabolism of estradiol in women with breast cancer. Proc Natl Acad
Sci USA. 79:3047–3051. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fishman J, Schneider J, Herschkopf RJ and
Bradlow HL: Increased estrogen 16alpha-hydroxylase activity in
women with breast and endometrial cancer. J Steroid Biochem.
20:1077–1081. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Telang NT: Oncogenes, estradiol
biotransformation, and mammary carcinogenesis. Ann NY Acad Sci.
784:277–287. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suto A, Telang NT, Tanino H, Takeshita T,
Ohmiya H, Osborne MP and Kubota T: In vitro and in vivo modulation
of growth regulation in the human breast cancer cell line MCF-7 by
estradiol metabolites. Breast Cancer. 6:87–92. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lottering ML, Haag M and Segers JC:
Effects of 17beta-estradiol metabolites on cell cycle events in
MCF-7 cells. Cancer Res. 52:5926–5932. 1992.PubMed/NCBI
|
|
25
|
Schneider J, Huh MM, Bradlow HL and
Fishman J: Antiestrogen action of 2-hydroxyestrone on MCF-7 human
breast carcinoma cells. J Biol Chem. 259:4840–4845. 1984.PubMed/NCBI
|
|
26
|
Campbell MJ, Hamilton B, Shoemaker M,
Tagliaferri M, Cohen I and Tripathy D: Anti-proliferative activity
of Chinese medicinal herbs on breast cancer cells in vitro.
Anticancer Res. 22:3843–3852. 2002.PubMed/NCBI
|
|
27
|
Chiu JH, Chang C, Wu JC, Liu HJ, Wen CS,
Hsu CH, Chen JL, Tseng LM, Chen WS and Shyr YM: Screening to
identify commonly used Chinese herbs that affect ERBB2 and ESR1
gene expression using the human breast cancer MCF-7 cell line. Evid
Based Complement Alternat Med. 2014:9654862014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Telang N: Putative cancer-initiating stem
cells in cell culture models for molecular subtypes of clinical
breast cancer. Oncol Lett. 10:3840–3846. 2015.PubMed/NCBI
|
|
29
|
Zhou W, Kallifatidis G, Baumann B, Rausch
V, Mettern J, Gladkich J, Giese N, Moldenhauer G, Wirth T, Büchler
MW, et al: Dietary polyphenol quercetin targets pancreatic cancer
stem cells. Int J Oncol. 37:551–561. 2010.PubMed/NCBI
|
|
30
|
Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji
J, Mason MD and Jiang WG: Traditional Chinese medicine in the
prevention and treatment of cancer and cancer metastasis. Oncol
Lett. 10:1240–1250. 2015.PubMed/NCBI
|
